Feb. 28, 2006 -- The US Food and Drug Administration (FDA) has approved hepatitis B immune globulin [human] injection for the treatment of acute exposure to hepatitis B virus; a supplemental ...
(MENAFN- EIN Presswire) market-insights.jpeg" width="300" height="88" alt="Hepagam B market Report 2025 : Market Size, Trends, And Global Forecast 2025-2034" style ...
January 27, 2007 —The European Commission has approved valsartan plus amlodipine besylate tablets for the treatment of hypertension in patients who do not achieve adequate blood pressure control with ...
Kamada ( ($IL:KMDA) ) has shared an announcement. On December 18, 2025, Kamada Ltd. announced it has secured a two-year extension to an existing ...
HepaGam B is a hyperimmune product containing antibodies specific for hepatitis B virus. Hyperimmunes are purified preparations of specific immune globulins isolated from blood plasma. Cangene is one ...
Readers are referred to the cautionary notes regarding Forward-looking and risk information at the end of this release Listed TSX, Symbol: CNJ TORONTO and WINNIPEG , Oct. 19 /CNW/ - Cangene ...
Cangene Corporation has reports that its HepaGam B® (Hepatitis B Immune Globulin (Human) Injection) has been approved by the Biologics and Genetic Therapies Directorate of Health Canada for treating ...
REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived ...
WASHINGTON, April 6 (Reuters) - Cangene Corp. won U.S. approval to promote its injectable HepaGam B product to prevent reinfection with the hepatitis B virus in certain liver transplant patients, ...
The Business Research Company's Key Market Driver In Hepagam B industry 2025: Rising Hepatitis B Prevalence To Fueling Growth It will grow to $XX million in 2029 at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback